Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AEF0117
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Indivior
Deal Size : Not Applicable
Deal Type : Not Applicable
Indivior Updates Aelis Farma's Phase 2B Results for Cannabis Use Disorder
Details : AEF0117 is an oral drug candidate, being evaluated for its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD).
Brand Name : AEF0117
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
Lead Product(s) : AEF0117
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Indivior
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AEF0117
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Indivior
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Following the promising results of a Phase 2a study showing that AEF0117 reduced the subjective effects of cannabis and cannabis self-administration in subjects with moderate to severe CUD.
Brand Name : AEF0117
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : AEF0117
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Indivior
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AEF0117
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Indivior
Deal Size : $130.0 million
Deal Type : Collaboration
Details : Indivior has entered into a strategic collaboration with Aelis Farma ("Aelis"), a private biotechnology company based in Bordeaux, France, that includes an exclusive option and license agreement (the "Agreement") for the global rights to AEF0117.
Brand Name : AEF0117
Molecule Type : Small molecule
Upfront Cash : $30.0 million
June 08, 2021
Lead Product(s) : AEF0117
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Indivior
Deal Size : $130.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?